Singapore’s medtech innovation ecosystem continues to demonstrate its strength with the development of a novel fluorescent nanosensor designed to detect indole-3-propionic acid (IPA), a gut microbiome-derived metabolite increasingly studied as a biomarker of gut-related biology and broader health states. Developed by a research collaboration involving National Institute of Education (NIE) NTU, Singapore-MIT Alliance for Research and Technology (SMART), National University Hospital (NUH) and National University of Singapore (NUS), the technology represents a step toward faster, more accessible diagnostic workflows and highlights the potential of the gut biomarker diagnostics market, says GlobalData, a leading intelligence and productivity platform.

The platform is reported to be the first optical nanosensor specifically engineered to detect IPA, which has been associated in research with inflammation, metabolic disorders, and chronic diseases. By enabling rapid optical detection, the nanosensor could help accelerate the measurement of IPA in research and, subject to clinical validation, may support future monitoring applications.

Nidhi Bharti, Medical Devices Analyst at GlobalData, comments: “The innovation represents a significant step forward in gut microbiome research and precision diagnostics. As evidence linking gut microbiome activity to gastrointestinal and metabolic conditions continues to evolve, demand for diagnostic solutions that provide timely and clinically actionable insights will rise.”

Unlike conventional mass spectrometry-based methods, which often require specialized laboratory infrastructure and lengthy processing times, the fluorescent nanosensor delivers optical readouts within minutes. This streamlined approach could improve accessibility and efficiency of biomarker testing and support broader adoption in both research and clinical settings.

Bharti continues: “Beyond diagnostics, the platform may support pharmaceutical and therapeutic research by enabling functional studies of microbiome-related interventions, probiotics, and novel treatment strategies.”

Bharti concludes: “The broader significance of this innovation lies in its potential to bridge the gap between laboratory-based biomarker analysis and real-world clinical application. As healthcare systems increasingly prioritize preventive care and personalized treatment pathways, technologies that enable faster and more convenient biomarker assessment are expected to gain substantial attention.”